iHeart Japan
iheartjapan.jp
Actively hiring
Regenerative Medicine
Biotechnology
Health Care
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
iHeart Japan develops allogeneic regenerative medical products derived from human induced pluripotent stem (iPS) cells targeting heart failure. It also provides in vitro research tools and cardiomyocyte platforms for cardiotoxicity screening and efficacy testing to pharmaceutical and biotechnology customers. The company aims to realize regenerative therapies that reduce reliance on heart transplantation and improve outcomes for patients with severe cardiac disease.